The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
ADCETRIS Takeda Pharmaceuticals Australia Pty Ltd
Product name
ADCETRIS
Accepted date
Jan-2025
Active ingredients
Brentuximab vedotin
Proposed indication
ADCETRIS is for the treatment of adult patients with previously untreated Hodgkin Lymphoma, in combination with a cocktail of other anti-cancer drugs.
Application type
C (new indication)
Publication date
Jan-2025